MEN Angela 门宇欣

Dr. Men Yuxin, Angela

  • Chief Medical Officer for Haichang Biotech
  • Chief Executive Officer for The WhiteOak Group Inc

Dr. Men joined the U.S. Food and Drug Administration (FDA) in 2003, and has served as senior/master clinical pharmacology reviewer, and team leader in the Office of Clinical Pharmacology, Center for Drug Evaluation (CDER), mainly responsible for evaluation of oncology and neurological drugs IND/NDA/BLA. In her nearly 18 years of drug regulatory career, she has reviewed/approved more than 2,000 new drug applications. She has received more than 50 awards from FDA, including Distinguished Service Award, Excellent Mentor Award, Distinguished Leadership Award and Excellent Regulatory Science Award. She has led many research projects related to drug review, won 12 FDA research grants, and participated in leading the development of several FDA guidelines. In May 2022, Dr. Men was recommended by PhIRDA to become an expert in the working group of ICH E21: Inclusion of Pregnant and Breastfeeding Individuals in Clinical Trials guidelines.
Dr. Men is the vice president of the Chinese Biopharmaceutical Association – USA, the board member and vice president of the Chinese FDA Expert Association, and she is also the member of the Federal Asian Pacific American Committee (FAPAC) and the assistant chairman of the community outreach department. She hosted and served as the organizer or lecturer for many national and international conferences and made great contributions to building a communication bridge between China and the United States in biopharmaceutical field. Dr. Men graduated from Tianjin Medical University with a bachelor’s degree in clinical medicine and obtained her Ph.D degree in pharmaceutical sciences from Virginia Commonwealth University. Since July 2021, she has served as the chief medical officer of Haichang Biotech. She has also served as the CEO of its subsidiary in US, The WhiteOak Inc. since early 2023.